Common cold

The common cold is an acute, usually mild and self-limiting infection of the upper respiratory tract, involving the nose, sinuses, pharynx and larynx. Its typical picture is a sore throat, sneezing, runny or blocked nose, cough and malaise, usually without high fever. Adults average a few episodes a year and children considerably more. Because it is so frequent, it is among the most common reasons people visit a doctor or stay home from work and school, and it is a major trigger of asthma attacks. No vaccine or antiviral drug is in routine use, so the illness is managed by treating symptoms while the immune system clears the virus.

Colds are not caused by a single virus. About half of cases involve one of the more than 160 types of rhinovirus, a small non-enveloped RNA virus. Several human coronaviruses that are distinct from SARS-CoV-2, along with influenza viruses, parainfluenza viruses, respiratory syncytial virus and others, account for most of the remainder. Infection starts when viruses reach the nasal lining, and the symptoms arise mainly from the host's inflammatory and immune response rather than from extensive direct tissue damage. Transmission occurs through droplets, direct contact and contaminated surfaces. Immunity after infection is short-lived and type-specific, which explains why people can catch colds repeatedly throughout life.

This entry covers the clinical course and the viruses behind it, how the infection spreads and how the immune system responds, how colds are diagnosed and which complications matter, and what symptomatic care, prevention and research into treatment look like. It also covers the epidemiological and economic burden, the history of how colds came to be understood as viral infections, the long-standing folk belief about cold exposure, and the open questions that remain for researchers.

Clinical picture and symptom course

After an incubation period of roughly 24–72 hours, symptoms commonly begin with a scratchy or sore throat, followed by sneezing, rhinorrhea (a runny nose), nasal obstruction, and malaise. Mild headache or muscle aches may accompany the nasal symptoms, but marked systemic illness is less characteristic. This sequence is a typical pattern rather than a fixed progression: throat discomfort, nasal discharge, congestion, and cough can overlap from the beginning. In a community study published in 2015, several symptom groups occurred together during the first four days; sore throat was the most bothersome symptom on day 1, nasal congestion on days 2–5, and cough on days 6–7. (merckmanuals.com)

Body temperature is usually normal, particularly in colds caused by rhinoviruses or seasonal coronaviruses. Low-grade fever can occur, but fever is not a defining feature of an uncomplicated cold. The predominance of nasal and throat symptoms, relatively gradual onset, and generally mild body aches contrast with influenza, which more often begins abruptly with fever, pronounced aches, headache, and weakness. These differences are probabilistic rather than diagnostic: some people with influenza have no fever, and the symptom patterns overlap sufficiently that temperature alone cannot distinguish the infections. (merckmanuals.com)

Nasal discharge is often clear, watery, and profuse early in the illness, becoming more mucoid or thicker as the cold progresses. This change reflects alterations in the composition of the secretions, not necessarily a change in the infectious agent. A 1993 experimental rhinovirus study found that the initial increase in nasal secretions was predominantly associated with increased vascular permeability, allowing plasma proteins to enter the secretions. A separate human challenge study published in 1998 demonstrated increased mucus constituents after infection, providing a mechanism for the progression from watery rhinorrhea to a more mucoid discharge. (sciencedirect.com)

Secretions may become white, yellow, or green after two or three days. Inflammatory cells contribute to this appearance: increased numbers of neutrophils can produce whitish or yellow discharge, while their enzyme myeloperoxidase can contribute a green coloration. Such changes occur during viral infection and do not, by themselves, establish secondary infection with bacteria. Accordingly, thick or colored nasal mucus is not sufficient evidence of a bacterial complication or an indication for an antibiotic. (pmc.ncbi.nlm.nih.gov)

Cough is common and may remain after throat discomfort and other early symptoms have subsided, often extending into the second week. Its frequency and persistence help explain its prominence in patient surveys. The US ACHOO survey, conducted in October 2012 among 3,333 online respondents and published in 2015, identified cough as the most frequently reported cold symptom, at 73.1%; it typically began one to five days after cold onset, and 35.2% reported a duration exceeding six days. These were retrospective reports subject to recall bias, not universal estimates: the 2015 community study found that cough was not usually the most frequent symptom, although it became especially bothersome later in the illness. (merckmanuals.com)

Causative viruses

Rhinoviruses are the most frequent cause of the common cold, accounting for roughly half of episodes in many studies. In a 1998 investigation by Mika J. Mäkelä and colleagues, rhinoviruses were identified in 105 of 200 young adults with colds, or 52.5%. They comprise three species, rhinovirus A, B and C, rather than a single uniform pathogen. A 2023 study described 169 recognized types: 80 in species A, 32 in B and 57 in C. Thus, “more than 160 types” refers to diversity within rhinoviruses, not to the number of different virus families capable of producing a cold. (pmc.ncbi.nlm.nih.gov)

The higher estimate that rhinoviruses cause “up to 80%” of colds appears, for example, in the sponsor-provided description of the ColdZyme human-challenge trial NCT02522949. This upper estimate should not be treated as a fixed, year-round proportion: attribution depends on the population, sampling period and detection methods. Mäkelä and colleagues cited an autumn study in which rhinoviruses were detected in 276 of 346 cold episodes, approximately 80%; in their own study, the proportion reached 92% among 36 participants recruited during an autumn outbreak. Such concentrated outbreak observations differ from estimates obtained across several seasons. (ctv.veeva.com)

Four common human coronaviruses—HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1—also cause colds. In the 1998 adult study, OC43 or 229E infection was identified in 17 of 200 participants, or 8.5%; that estimate did not cover all four viruses now recognized. Their contribution is seasonal: a US surveillance analysis published in 2022 found that, across six seasons before 2020–2021, aggregate coronavirus activity peaked between January 6 and February 13. These viruses usually cause mild upper-airway illness, but can also cause bronchitis or pneumonia, particularly in infants, older adults and people with cardiopulmonary disease or weakened immunity. They are distinct from SARS-CoV-2, the coronavirus responsible for COVID-19. (pmc.ncbi.nlm.nih.gov)

Additional causes include human parainfluenza viruses, adenoviruses, non-rhinovirus enteroviruses, including EV-D68, and human metapneumovirus. The boundaries of “common cold” vary between research and public-health usage. Older studies enrolling patients by their cold symptoms also identified influenza viruses and respiratory syncytial virus; current CDC guidance distinguishes influenza, RSV infection and COVID-19 from colds, while acknowledging that all can produce cold-like symptoms. Consequently, studies of a clinically defined cold syndrome and studies restricted to particular cold-causing viruses need not yield the same distribution of pathogens. (cdc.gov)

More than one virus may be detected during the same episode. The 1998 study found double viral infections in 10 participants, or 5%, including rhinovirus with OC43, influenza A or B, parainfluenza virus, adenovirus or enterovirus. Conversely, no viral cause was established in 31% of participants despite culture, antigen testing, PCR and paired-serum testing; this is a study-specific unidentified fraction, not evidence that those episodes were nonviral. Symptoms alone cannot reliably identify the responsible virus or consistently separate an uncomplicated cold from influenza or COVID-19, because their clinical manifestations overlap. (pmc.ncbi.nlm.nih.gov)

Virus biology and entry into the airway

Rhinoviruses are small, non-enveloped viruses in the family Picornaviridae: their genetic material is enclosed in a protein shell, or capsid, rather than a lipid membrane. The particle is approximately 30 nanometres in diameter and has icosahedral symmetry. Its capsid contains 60 copies each of four structural proteins: VP1, VP2 and VP3 form the outer surface, while the smaller VP4 lies internally. The genome is positive-sense, single-stranded RNA, meaning that, once released into the cytoplasm, it can serve directly as a template for protein synthesis. Translation produces a large polyprotein that viral enzymes cut into structural proteins and proteins required for replication; a viral RNA-dependent RNA polymerase then makes new RNA genomes through a complementary negative-strand intermediate. (pmc.ncbi.nlm.nih.gov)

The coronaviruses associated with colds have a different architecture despite also carrying positive-sense RNA. Their particles possess a lipid envelope containing membrane and envelope proteins, with prominent, club-shaped projections formed by the spike glycoprotein. Inside the envelope, nucleocapsid protein associates with the RNA genome. The spikes provide the characteristic crown-like outline and participate in attachment to cells and membrane fusion. Thus, coronavirus entry involves fusion of a viral lipid membrane with a cellular membrane, whereas rhinoviruses must deliver RNA across a cellular membrane without possessing an envelope of their own. (pmc.ncbi.nlm.nih.gov)

For rhinoviruses, attachment depends on recognition of particular cell-surface receptors. The traditional “major receptor group,” comprising types from rhinovirus A and B, binds intercellular adhesion molecule 1, or ICAM-1. The “minor receptor group,” restricted to rhinovirus A, uses members of the low-density lipoprotein receptor family, including LDLR, VLDLR and LDLR-related protein. These categories do not encompass rhinovirus C. In 2015, Yury Bochkov and colleagues showed that expression of cadherin-related family member 3, or CDHR3, allowed previously unsusceptible cells to support rhinovirus C attachment and replication, identifying a distinct receptor pathway. (pmc.ncbi.nlm.nih.gov)

After attachment, rhinovirus particles are internalized into membrane-bound compartments called endosomes. Receptor binding and endosomal acidification contribute differently to release of the genome, a process termed uncoating. ICAM-1 can actively prime major-group capsids for structural changes, with mildly acidic conditions promoting uncoating in some types. For the minor-group prototype rhinovirus A2, LDL-receptor-family proteins deliver the particle into the endosomal pathway; acidification subsequently triggers capsid rearrangement and transfer of RNA into the cytoplasm. These steps distinguish simple attachment from productive entry: a particle must not only bind a cell but also release its genome into the compartment where replication occurs. (pmc.ncbi.nlm.nih.gov)

Most rhinovirus isolates replicate more efficiently at approximately 33–35 °C, temperatures characteristic of the nasal cavity, than at 37 °C. This preference partly reflects temperature-dependent cellular defenses rather than an absolute inability to grow at body temperature. In 2015, Ellen Foxman and colleagues found that mouse airway cells infected with mouse-adapted rhinovirus mounted stronger interferon responses at 37 °C than at 33 °C; disrupting antiviral signaling partly restored replication at the warmer temperature. Their 2016 experiments in human bronchial epithelial cells also implicated increased infected-cell death and the RNA-degrading enzyme RNase L in restriction at 37 °C. Temperature therefore helps explain the preference for the upper airway, but does not constitute an impermeable barrier to infection elsewhere in the respiratory tract. (pubmed.ncbi.nlm.nih.gov)

Transmission and seasonality

Cold-causing viruses spread through respiratory particles, direct contact with contaminated hands, and indirect contact with contaminated objects. Particles released during coughing and sneezing can be inhaled or deposited on exposed mucous membranes. Hand-mediated transmission involves a further step: infectious secretions pass onto a hand, either through contact with an infected person or through touching a contaminated surface, and are then transferred to the eyes, nose, or mouth. Door handles, phones, taps, and shared household objects can therefore act as fomites. These pathways are not mutually exclusive, and their relative importance differs between viruses and exposure settings. (cdc.gov)

Experiments have demonstrated both surface-mediated and airborne transmission of rhinovirus. In studies conducted in 1980–1981 and published in 1982, Jack M. Gwaltney Jr. and J. Owen Hendley found that 5 of 10 volunteers became infected after handling contaminated coffee-cup handles and subsequently touching their nasal or conjunctival mucosa; 9 of 16 became infected after equivalent exposure to contaminated plastic tiles. Conversely, a 1987 experiment by Elliott C. Dick and colleagues demonstrated transmission through aerosols during 12-hour card-playing sessions. Infection occurred in 10 of 18 recipients prevented from touching their faces, compared with 12 of 18 unrestricted recipients, a difference that was not statistically significant. These controlled experiments establish that both routes are possible, rather than providing a universal estimate of their contribution to naturally acquired colds. (pubmed.ncbi.nlm.nih.gov)

Infectious rhinovirus can persist on objects for hours, although detection of viral genetic material does not necessarily indicate that viable virus remains. Birgit Winther and colleagues’ 2011 household study detected rhinovirus RNA on 66 of 160 sampled surfaces in the homes of adults with rhinovirus-positive colds, including refrigerator handles, remote controls, and bathroom taps. In a related transfer experiment using contaminated objects, infectious virus was recovered from 22% of fingertips after contact with deposits aged one hour, compared with 3% after 24 hours and none after 48 hours. The findings document a surface-to-hand pathway while also showing the decline in recoverable infectivity over time. (onlinelibrary.wiley.com)

Repeated close contact concentrates opportunities for spread in households, schools, daycare centres, and crowded workplaces. Children also connect otherwise separate household contact networks. The Utah BIG-LoVE study followed 26 households with weekly nasal sampling from August 2009 to August 2010; an analysis published in 2018 found that rhinovirus acquisition became more likely as the proportion of infected household members increased. Children, particularly symptomatic children, showed the strongest evidence of transmission within households, while infection among school-aged children was associated with acquisition between households. These were statistical associations derived from longitudinal sampling, not direct observations of every transmission event. (cdc.gov)

Rhinoviruses circulate throughout the year, with a prominent autumn peak and a second spring peak commonly observed in temperate Northern Hemisphere populations. US pediatric surveillance covering 2016–2021 detected the combined rhinovirus/enterovirus group year-round, with peaks in late summer or early autumn and spring; the combined test category limits attribution to rhinovirus alone. Seasonal coronaviruses follow a more winter-centred pattern. A 2022 analysis of US surveillance data found that, across six seasons before 2020–2021, coronavirus activity began in October–November, peaked in January–February, and ended in April–June; 93.2% of detections fell within those seasonal boundaries. Adenoviruses can circulate year-round, whereas human metapneumovirus and parainfluenza type 3 often show spring activity. Seasonal timing varies geographically and can be disrupted by changes in contact patterns: the US seasonal-coronavirus onset in 2020–2021 was delayed by 11 weeks relative to the preceding six-season mean. (jamanetwork.com)

Pathogenesis and inflammatory response

Cold viruses replicate in epithelial cells lining the nose and adjacent upper airway, initiating innate immune responses rather than simply destroying the mucosal surface. Much of the mechanistic evidence comes from experimental rhinovirus infection. In a 1984 study by Birgit Winther and colleagues, serial nasal biopsies from 20 infected volunteers and 10 sham-inoculated controls showed increased inflammatory-cell infiltration without widespread epithelial destruction. In cultured human nasal epithelium, rhinovirus and coronavirus 229E likewise replicated without the conspicuous cell damage produced by influenza A or adenovirus under the same experimental conditions. These findings distinguish inflammatory symptom production from direct virus-induced tissue injury, although the relative contributions vary among viruses. (pubmed.ncbi.nlm.nih.gov)

Epithelial cells detect viral RNA through intracellular recognition systems. Experiments in human airway epithelial cells have identified TLR3 and MDA5 as important sensors for the interferon response to rhinovirus replication. Their activation induces interferon-β and interferon-λ, together with antiviral genes and inflammatory cytokines. The antiviral and inflammatory components have different functions: interferon signaling helps restrict replication, whereas chemotactic mediators recruit immune cells into the infected tissue. Interleukin-8, also called CXCL8, and granulocyte colony-stimulating factor are closely associated with neutrophil accumulation in nasal secretions during experimental infection. These recruited cells become part of the local inflammatory response rather than evidence, by themselves, of bacterial infection. (pmc.ncbi.nlm.nih.gov)

Vascular leakage and glandular secretion contribute to rhinorrhea, while local vascular changes and swelling contribute to obstruction. A 1993 challenge study involving 20 volunteers with allergic rhinitis and 18 nonallergic controls found that plasma-derived proteins predominated in the early increase in nasal secretions, whereas glandular products became more prominent later. Kinins, including bradykinin, provide a mechanistic link between infection, increased vascular permeability and symptoms. In a 1988 experiment by David Proud and colleagues, intranasal bradykinin administered to eight subjects caused dose-dependent obstruction, rhinorrhea and persistent sore throat without increasing histamine release. Another challenge study found irritation and sneezing at higher bradykinin doses. Histamine therefore should not be treated as the principal mediator of an uncomplicated rhinovirus cold: unlike the characteristic allergic response, classic rhinovirus experiments found no consistent rise in nasal histamine during illness. (sciencedirect.com)

Human challenge studies directly connect symptom burden with the magnitude of local inflammation. In Ronald Naclerio and colleagues’ 1988 investigation, 25 of 27 virus-inoculated volunteers had positive cultures, but only 15 developed clinical illness. Kinin concentrations increased more than tenfold in the infected, symptomatic group, while remaining relatively unchanged in infected volunteers without illness. In 1998, Ronald Turner and colleagues studied 54 experimentally infected subjects and 20 sham-inoculated controls; nasal IL-8 concentrations were higher in symptomatic infected subjects on days 2–4 and correlated with obstruction, rhinorrhea and albumin leakage. These associations support an important contribution from the host response, but do not establish that every stronger immune response produces worse symptoms. A separate experimental study found that a higher airway interferon-γ-to-IL-5 expression ratio was associated with fewer cold symptoms and faster viral clearance. (pubmed.ncbi.nlm.nih.gov)

Prior exposure and immune maturation help explain differences between individuals. In a 1998 challenge study of 133 healthy adults, higher pre-existing neutralizing antibody titers against the challenge rhinovirus were associated with reduced infection and milder illness, demonstrating that baseline protection modifies the response to a comparable exposure. Age also changes the cellular environment of the nasal mucosa. A study of children aged 0–2 years, including 20 rhinovirus infections, seven respiratory syncytial virus infections and 40 controls, found increasing nasal T-cell numbers with age and increased T-cell and macrophage numbers during infection. T-cell changes were more closely related to age, whereas macrophage changes were more closely related to accumulated respiratory infections. Such observations document developmental differences in local immunity without establishing a simple rule that younger age necessarily produces a stronger or weaker inflammatory response. (pubmed.ncbi.nlm.nih.gov)

Immunity and reinfection

Rhinovirus infection induces adaptive immunity, including neutralizing antibodies and virus-reactive T cells, but protection is predominantly type-specific rather than protection against colds generally. Antibodies recognize exposed structures on the viral capsid and can prevent infection by the corresponding virus type. This immunity is not necessarily short-lived: in a 1989 challenge study by Wendy Barclay and colleagues, antibodies to rhinovirus type 2 began increasing one to two weeks after infection and peaked at five weeks. Eight infected volunteers maintained their specific antibodies for at least a year and resisted rechallenge; two whose antibody levels declined became infected again, although without illness. A 2023 study by Yury Bochkov and colleagues, examining longitudinal plasma samples collected between ages 2 and 18 years, likewise found durable neutralizing responses to rhinovirus A and C. Recurrent colds therefore do not imply that all immunity disappears soon after recovery. (pubmed.ncbi.nlm.nih.gov)

The principal obstacle to broad protection is antigenic diversity. Historical classifications distinguished approximately 100 rhinovirus A and B serotypes by their reactions with neutralizing antibodies; subsequent molecular classification added further A and B types and numerous rhinovirus C genotypes. The 2013 classification proposals, for example, extended the C-type series through C51. A serotype is defined by antibody recognition, whereas a genotype is distinguished by sequence differences, so the two counts are not interchangeable. Most antibodies that efficiently neutralize one type do not neutralize unrelated types. Bochkov and colleagues found limited cross-neutralization, principally between genetically related viruses, rather than species-wide protection. An individual can consequently retain immunity to earlier infections while remaining susceptible to many other circulating rhinoviruses. (pubmed.ncbi.nlm.nih.gov)

Cellular immunity can recognize a broader range of rhinoviruses than neutralizing antibodies. In a 1997 study, James Gern and colleagues isolated 31 CD4 T-cell clones responding to rhinovirus 16 or 49 and tested them against five serotypes. Only two clones responded exclusively to the original virus; the others responded to between two and five serotypes. This demonstrated recognition of shared as well as type-restricted viral antigens. Such recall responses may contribute to antiviral activity after exposure to another type, but cross-reactive T-cell recognition does not establish that infection itself will be prevented; the same responses can also contribute to airway inflammation. (pubmed.ncbi.nlm.nih.gov)

Protection at the nasal surface also differs from immunity measured in blood. Immunological memory includes memory B cells and T cells, but preventing initial infection requires effective defenses at the site where virus enters. An experimental study using rhinoviruses A16 and A39 found rapidly recruited, cross-reactive T-bet-positive memory B cells in infected nasal tissue. Local cross-reactive IgG peaked around days four to five, whereas later responses included type-specific IgA. The investigators proposed that the subsequent departure of these recruited cells, and their apparent failure to establish long-lived antibody secretion, could explain waning broad nasal protection. This is a mechanism supported by that experimental model, not evidence that all nasal memory rapidly vanishes: separate human upper-airway research identified resident memory B- and T-cell populations that remained stable during sampling over more than a year. (pmc.ncbi.nlm.nih.gov)

A different, short-term form of cross-protection was reported in 2025 by Camille Moore and colleagues in the HEROS cohort. Testing 10,493 longitudinal nasal swabs from 1,156 participants, they found that rhinovirus infection within the preceding 30 days was associated with a 48% lower subsequent risk of SARS-CoV-2 infection. Among participants who acquired SARS-CoV-2, recent rhinovirus infection was associated with a 9.6-fold lower viral load. Rhinovirus induced 22 antiviral-defense genes belonging to a signature associated with lower SARS-CoV-2 loads; children expressed this signature more strongly than adults and experienced more rhinovirus infections. These findings link recent colds to temporarily heightened airway defenses, consistent with innate immunity and interferon-associated viral interference rather than rhinovirus antibodies recognizing SARS-CoV-2. The observational association does not establish lasting immunity to COVID-19 or prevention of infection in every exposed individual. (pubmed.ncbi.nlm.nih.gov)

Diagnosis and differential diagnosis

The common cold is usually a clinical diagnosis based on the history and physical examination, rather than laboratory identification of a particular virus. Nasal discharge, congestion, sneezing and sore throat, with relatively mild systemic symptoms, support the diagnosis; the timing of symptoms and locally circulating respiratory infections help interpret the presentation. High fever, difficulty breathing or chest pain are not typical of an uncomplicated cold and broaden the differential diagnosis. Routine laboratory testing is generally unnecessary when identifying the pathogen would not alter clinical management. (merckmanuals.com)

Influenza more often begins abruptly, with prominent fever, chills, muscle aches, headache and fatigue, whereas a cold is generally milder and dominated by nasal symptoms. These differences are probabilistic, not definitive: influenza and COVID-19 can produce cold-like symptoms, and symptoms alone cannot reliably establish the causative virus. Pathogen-specific testing therefore has particular importance when the result affects eligibility for antiviral treatment, especially in people at increased risk of severe illness. Allergic rhinitis also causes sneezing and watery nasal discharge, but itchy, watery eyes, recurrent symptoms associated with an allergen or season, and pale, swollen nasal mucosa favor allergy. This distinction separates an infectious syndrome from an allergen-related disorder requiring different management. (cdc.gov)

Streptococcal pharyngitis is more likely when a sudden sore throat and painful swallowing accompany fever, tender anterior cervical lymph nodes, palatal petechiae or tonsillar exudate. Cough, rhinorrhea and hoarseness instead favor viral infection. In the absence of clear viral features, examination alone cannot distinguish group A streptococcal infection from viral pharyngitis: confirmation uses a rapid antigen detection test or throat culture. Rapid tests have high specificity but variable sensitivity; CDC guidance specifies culture confirmation of a negative rapid test in symptomatic children aged three years or older. Confirmed streptococcal pharyngitis warrants antibiotic treatment, unlike an uncomplicated cold. (cdc.gov)

Acute bacterial rhinosinusitis is distinguished primarily by the severity and trajectory of symptoms, not mucus color alone. Thick or purulent nasal secretions can occur during a viral cold. CDC adult outpatient criteria identify three patterns supporting bacterial disease: symptoms persisting for more than ten days without improvement; severe symptoms lasting more than three to four days, including fever of at least $39\,^\circ\mathrm{C}$ with purulent discharge or facial pain; or worsening after initial improvement. Routine sinus radiographs are not recommended. These criteria help distinguish a bacterial process with potential antibiotic indications from the nasal and sinus inflammation accompanying an ordinary viral infection. (merckmanuals.com)

When virological identification is needed, reverse-transcription quantitative polymerase chain reaction (RT-qPCR) detects viral RNA after conversion to DNA. Multiplex molecular panels test for several respiratory pathogens in one assay, rather than inferring the agent from symptoms. Molecular tests are generally more sensitive than rapid antigen tests, so a negative antigen result does not necessarily exclude influenza or COVID-19. Detection and rhinovirus typing are separate procedures: sequencing of amplified capsid-coding regions, particularly VP4/VP2, can assign a detected rhinovirus to a species and type. In a 2014 assay-development study, Yury A. Bochkov and colleagues successfully detected and typed rhinoviruses in 99% of samples previously positive in multiplex diagnostic assays. Such typing serves research and surveillance rather than routine cold diagnosis; it can, for example, help distinguish prolonged detection of the same virus from infection with a different type in sequential samples. (cdc.gov)

Complications and high-risk groups

Acute otitis media and sinusitis can develop during or after a cold. Infection and local inflammation impair Eustachian-tube function, allowing fluid to accumulate behind the eardrum; viruses and nasopharyngeal bacteria may both contribute to middle-ear disease. In a prospective study published in 2008, Tasnee Chonmaitree and colleagues followed 294 children aged six months to three years. Among 864 upper-respiratory infection episodes with virological investigations, 37% were complicated by acute otitis media and another 24% by otitis media with effusion, which lacks the acute inflammatory presentation. Approximately one-third of rhinovirus-associated episodes developed acute otitis media. These figures describe closely monitored young children, not the complication rate among all people with colds. Sinus involvement likewise does not necessarily represent a secondary bacterial infection: rhinoviruses themselves can cause sinus disease. (pmc.ncbi.nlm.nih.gov)

Cold viruses can also cause lower-respiratory disease rather than remaining confined to the nose and throat. Rhinoviruses are recognized causes of wheezing, bronchiolitis and pneumonia, particularly in infants and people with underlying illness. Pneumonia may reflect viral infection itself, a subsequent bacterial infection, or infection involving multiple pathogens. Prematurely born children and people with weakened immunity are among the groups identified by the US Centers for Disease Control and Prevention (CDC) as being at increased risk of severe rhinovirus illness. Thus, a lower-airway complication need not mean that an initially viral illness has become exclusively bacterial. (cdc.gov)

In older children and adults with asthma, rhinovirus infection can trigger an acute exacerbation. A 2008 experimental study by Simon Message and colleagues compared ten volunteers with asthma with fifteen without asthma: infection produced greater lower-respiratory symptoms, lung-function impairment, bronchial hyperreactivity and eosinophilic airway inflammation in the asthma group. Chronic obstructive pulmonary disease (COPD) is another important susceptibility factor. In Patrick Mallia and colleagues’ 2011 challenge study, ten of eleven successfully infected COPD participants met symptom criteria for an exacerbation. A subsequent experiment, published in 2012, detected secondary bacterial infection in 60% of COPD participants, compared with approximately 10% of controls; sputum viral load peaked on days 5–9, whereas bacterial load peaked on day 15. These small experimental studies establish mechanisms and temporal relationships, rather than population-wide complication probabilities. (pmc.ncbi.nlm.nih.gov)

Severe and fatal rhinovirus-associated pulmonary disease has been documented in immunocompromised patients, including people undergoing transplantation for hematological malignancies. In a 2017 study, Sachiko Seo and colleagues examined 697 hematopoietic-cell transplant recipients with rhinovirus detected in respiratory samples. Ninety-day overall mortality was 6% among 569 patients with upper-respiratory infection and 41% among 128 with lower-respiratory infection. These were all-cause mortality estimates in a highly vulnerable population, not rhinovirus-attributable fatality rates for ordinary colds. Lower monocyte counts, oxygen requirement and corticosteroid doses exceeding 1 mg/kg/day were associated with mortality after lower-respiratory infection; severe disease also occurred without identified copathogens. (pubmed.ncbi.nlm.nih.gov)

The endemic coronaviruses 229E, OC43, NL63 and HKU1 can also accompany lower-respiratory disease in very young children and older adults. A retrospective study published in 2022 examined 1,062 coronavirus-positive children hospitalized in Hebei, China, during 2015–2020: 82.8% were no older than three years, and 65.7% had lower-respiratory diagnoses. Those proportions concern hospitalized patients, not all infected children. Edward Walsh and colleagues’ surveillance of adult populations during the winters of 1999–2003, published in 2013, documented clinically significant 229E and OC43 infections among older adults and adults with underlying cardiopulmonary disease; OC43 was twice as common as 229E in the hospitalized cohort. (pubmed.ncbi.nlm.nih.gov)

Clinical guidance distinguishes uncomplicated symptoms from features warranting further assessment. CDC lists difficult or rapid breathing, dehydration, fever lasting more than four days, symptoms persisting beyond ten days without improvement, deterioration after initial improvement, and worsening chronic disease as reasons for medical review. Its common-cold fact sheet additionally identifies a temperature of at least 38 °C (100.4 °F) in an infant younger than three months as requiring prompt assessment. These features indicate possible complications or an alternative illness rather than identifying a particular pathogen. (cdc.gov)

Course, duration and age patterns

An uncomplicated cold generally improves within about seven to ten days, although complete disappearance of symptoms can take longer. Recovery is therefore better understood as a gradual reduction in illness rather than a fixed endpoint: cough and nasal discharge may remain after other symptoms have subsided. The US Centers for Disease Control and Prevention notes that runny nose and cough can last 10–14 days. These ranges describe the usual course, not a maximum duration shared by every patient. (doh.dc.gov)

Children often have a longer symptomatic course than the conventional “one-week cold” suggests. In a 2013 systematic review led by Matthew Thompson, pooled data from five studies indicated that approximately half of children with common-cold symptoms had improved by day 10; the investigators estimated, from the plotted recovery curves, that about 90% had improved by day 15. This latter figure was an approximate estimate rather than a directly calculated pooled percentile. The review separately found that acute cough resolved in about half of children by 10 days and in 90% by 25 days. Because the cough studies included respiratory illnesses other than uncomplicated colds, the 25-day figure cannot be treated as the expected duration of every cold-associated cough. Differences in symptom definitions, age, and the interval between illness onset and recruitment also contributed to variation between studies. (bmj.com)

The annual frequency of colds is substantially higher in early childhood than in adulthood. The Canadian Paediatric Society describes as many as eight to ten colds annually in children younger than two, whereas CDC estimates an average of two to three annually among US adults. The decline with age reflects both accumulated, virus-specific adaptive immunity and differences in exposure. Young children encounter many cold viruses for the first time, while childcare brings repeated contact with other children and their secretions. Protection acquired against one virus does not provide equivalent protection against the many other viruses capable of producing a cold. Consequently, repeated episodes in a young child can reflect successive infections rather than one continuously persisting illness. (caringforkids.cps.ca)

Children are also an important source of infection for other household members. In a Finnish study published in 2008, Ville Peltola and colleagues monitored eight families with a rhinovirus-positive index child and 16 comparison families for three weeks. Among families with a positive index child, detected rhinovirus infections amounted to 1.00 episode per sibling and 0.50 per parent, compared with 0.54 and 0.23, respectively, in comparison families. Molecular typing supported transmission within households and showed that several virus types could circulate simultaneously. Infections in children younger than seven were more often symptomatic; secondary infections in adults were frequently asymptomatic. Thus, counts of recognizable colds do not capture every infection occurring within a family. (pubmed.ncbi.nlm.nih.gov)

Repeated childhood episodes create caregiving demands alongside missed childcare, school, and parental work. A Finnish prospective birth-cohort study published in 2017 illustrates how this burden changes after entry into childcare: mean days per month with respiratory symptoms increased from 3.79 before centre-based daycare to 10.57 two months after entry, then declined with continued attendance. These were days with respiratory symptoms, not counts of laboratory-confirmed colds. Symptom days returned near baseline within the nine-month follow-up, but parental absence from work did not, partly because both parents were more likely to be working after childcare began. Family disruption therefore depends not only on illness duration but also on childcare arrangements and the availability of an adult caregiver. (utupub.fi)

Symptomatic care and the role of antibiotics

No medicine cures the common cold; treatment is directed at comfort rather than elimination of the infection. Clinical guidance includes rest, adequate fluids, and medicines for pain or fever, but these measures should not be confused with treatments that shorten viral illness. Acetaminophen, also called paracetamol, and ibuprofen can relieve aches and fever. A 2015 Cochrane review of nine randomized controlled trials, involving 1,069 participants, found that non-steroidal anti-inflammatory drugs improved headache, ear pain, and muscle or joint pain, but did not significantly shorten colds or clearly improve cough or rhinorrhea. Thus, the evidence supports their analgesic role more strongly than an effect on respiratory symptoms. (cdc.gov)

Saline nasal drops, sprays, and irrigation are used to moisten nasal passages and help clear secretions; in infants, saline may be combined with gentle bulb suction. Their inclusion in clinical guidance does not imply strong evidence that they alter the course of infection. A 2015 Cochrane review identified five trials involving 544 children and 205 adults with acute upper respiratory infections. Most comparisons showed no difference between saline and control treatment, although one larger pediatric trial found modest improvements in nasal secretion and obstruction scores. Small studies, heterogeneous outcome measures, and methodological limitations reduced confidence in the findings. Saline is therefore principally a supportive measure, with uncertain effects on illness duration. (fda.gov)

Decongestants reduce swelling of blood vessels in the nasal lining, temporarily opening the nasal airway. However, efficacy is limited and cannot be assumed for every preparation or age group. A 2016 Cochrane review included 15 studies with 1,838 participants, predominantly adults; repeated doses produced a small improvement in subjective congestion, but its clinical importance was uncertain, and evidence quality was low. The review could not establish effectiveness or safety in children. Prolonged use of topical decongestant sprays or drops can itself worsen nasal obstruction through rebound congestion; current British National Health Service guidance limits their use to five days. These drugs relieve obstruction rather than cure infection. (nhs.uk)

Official age restrictions distinguish general pediatric guidance from product labeling. The United States Centers for Disease Control and Prevention advises against routine over-the-counter cough and cold medicines in children younger than six years. The Food and Drug Administration specifically warns against products containing decongestants or antihistamines in children younger than two, while manufacturers label pediatric cough and cold products against use below four. Reported harms include convulsions, rapid heart rates, and potentially fatal reactions. During 2004–2005, an estimated 1,519 children younger than two received emergency-department treatment for adverse events associated with these medicines, including overdoses. Multi-ingredient preparations create an additional risk when two products contain the same drug, such as acetaminophen. (cdc.gov)

Antibiotics treat susceptible bacteria, not the viruses responsible for uncomplicated colds. They therefore have no role in routine cold treatment, and unnecessary exposure can cause rash, severe allergic reactions, or Clostridioides difficile infection, while contributing to antibiotic resistance. Antibiotic treatment becomes a separate consideration when clinical assessment identifies a bacterial complication, such as bacterial pneumonia, rather than merely persistent cold symptoms. Thickened or discolored nasal discharge alone does not establish such an indication: bacterial sinusitis is assessed from the overall severity and trajectory of illness. (cdc.gov)

Further assessment depends on findings inconsistent with an uncomplicated, improving upper respiratory infection. Clinicians consider breathing difficulty, hydration, vital signs, lung findings, and worsening after initial improvement. CDC criteria supporting assessment for acute bacterial sinusitis include symptoms persisting for more than ten days without improvement, severe symptoms for more than three to four days with fever of at least $39^\circ\mathrm{C}$ and purulent discharge or facial pain, or renewed deterioration after initial recovery. In children, labored breathing, blue lips, poor fluid intake with reduced urination, excessive sleepiness, or persistent ear pain warrant particular attention. Cold-like illness attributable to influenza or COVID-19 also has different treatment implications, because targeted antiviral treatment may be available. (cdc.gov)

Prevention and hygiene

Hand hygiene interrupts the transfer of virus-containing secretions from hands and objects to the eyes, nose, and mouth. Soap, friction, and rinsing remove contamination rather than depending solely on chemical inactivation. US Centers for Disease Control and Prevention (CDC) guidance specifies scrubbing for at least 20 seconds and washing after blowing the nose, coughing, or sneezing. A 2023 Cochrane review led by Tom Jefferson found that hand-hygiene programmes probably reduced acute respiratory illness by 14% relative to controls in nine trials involving 52,105 participants. These outcomes included respiratory illnesses other than laboratory-confirmed colds, so the estimate is not a rhinovirus-specific effect. (cdc.gov)

Evidence for individual hand-disinfection products is less consistent. In a randomized controlled trial published in 2012, Ronald B. Turner and colleagues assigned 212 young adults to either an antiviral hand treatment or no treatment during nine weeks of the autumn rhinovirus season. The preparation contained 62% ethanol plus citric and malic acids and was applied every three hours while participants were awake; it did not significantly reduce rhinovirus infection or rhinovirus-associated colds. This result distinguishes the effectiveness of a particular sanitizer regimen from that of broader hand-hygiene programmes. (pubmed.ncbi.nlm.nih.gov)

Cleaning frequently touched surfaces, including doorknobs, handrails, countertops, and shared toys, removes material that can contaminate hands. CDC guidance identifies soap- or detergent-based household cleaning as part of respiratory-virus prevention. However, reduced environmental contamination does not necessarily produce a measurable reduction in illness. A 2015 trial in 12 daycare nurseries caring for 587 children tested washing and disinfection of toys and linen every two weeks for three months. The intervention reduced detection of several respiratory viruses, including rhinovirus, but did not reduce sickness absence or alter recorded disease patterns. Surface cleaning therefore addresses one exposure pathway rather than replacing measures against close-contact and airborne exposure. (cdc.gov)

Covering coughs and sneezes with a tissue, promptly discarding it, and cleaning the hands limits dispersal of secretions; coughing into the elbow rather than the hands reduces contamination of objects subsequently touched. Avoiding close contact with symptomatic people and staying home during illness reduce opportunities for exposure in households, schools, and workplaces. CDC guidance updated on August 18, 2025, describes return to normal activities after symptoms have improved overall and fever has been absent without fever-reducing medication for at least 24 hours, followed by five days of additional precautions. This is general respiratory-virus guidance, not a cold-specific determination that infectiousness has ended. Improved ventilation and air filtration complement these measures by lowering the concentration of airborne particles indoors. (cdc.gov)

Face masks provide source control and filtration, with performance affected by fit, material, and consistent use, but direct evidence for preventing colds remains limited. In 2020, Nancy H. L. Leung and colleagues examined exhaled breath from symptomatic participants, including 54 with rhinovirus infection. Surgical masks reduced detection of seasonal-coronavirus RNA in aerosols, but did not significantly reduce rhinovirus RNA detection in droplets or aerosols; the experiment measured shedding, not subsequent infections. The 2023 Cochrane review likewise found no clear reduction in respiratory viral infection from community medical-mask interventions, while noting variable adherence, risk of bias, and uncertainty. These findings do not establish that masks have no filtering effect or that results for one virus necessarily apply to every cold-causing virus. (cdc.gov)

No licensed vaccine provides broad protection against the common cold. More than 200 respiratory viruses can cause the syndrome, and rhinoviruses alone have extensive antigenic diversity. Neutralizing antibodies generally recognize particular viral types, so protection against one does not reliably cover others. Limited durability of broadly protective airway immunity adds to this problem, although type-specific immunity can persist and should not be described as uniformly short-lived. A rhinovirus vaccine would also leave colds caused by unrelated viruses unaffected; vaccine-development approaches are considered separately. (cdc.gov)

Vaccines, antivirals and unproven remedies

No vaccine or specific antiviral therapy is approved for rhinovirus infection. Vaccine development has been hindered by the simultaneous circulation of many antigenically distinct types: an antibody response that neutralizes one type need not protect against others. Multivalent formulations attempt to overcome this limitation by including numerous viral antigens. In 2016, Sujin Lee and colleagues reported that an alum-adjuvanted, inactivated vaccine containing 50 rhinovirus types induced neutralizing antibodies against numerous types in rhesus macaques; related experiments tested 25-type formulations in mice. These were demonstrations of immunogenicity in animals, not evidence of clinical protection in humans. (cdc.gov)

Zinc lozenges and other zinc preparations have been evaluated separately for prevention and treatment. A 2024 systematic review by Daryl Nault and colleagues included 34 studies involving 8,526 participants. Zinc appeared to have little or no preventive effect, but eight treatment studies involving 972 participants suggested a mean reduction in cold duration of 2.37 days, with a 95% confidence interval of 0.53–4.21 days shorter. This was low-certainty evidence, with substantial differences between studies in formulations, doses, administration routes and outcome definitions. Treatment probably increased non-serious adverse effects, including unpleasant taste and gastrointestinal symptoms. Results for oral products cannot establish the safety of nasal preparations: intranasal zinc has been associated with loss of smell, sometimes permanent. (cochrane.org)

Evidence for vitamin C depends strongly on when supplementation begins. Harri Hemilä and Elizabeth Chalker’s 2013 Cochrane review found that regular supplementation did not materially reduce cold incidence in the general population. However, across 31 comparisons covering 9,745 cold episodes, regular supplementation reduced duration by approximately 8% in adults and 14% in children. Five trials involving 598 participants exposed to brief periods of severe physical exertion, including marathon runners, skiers and soldiers undertaking subarctic exercises, found roughly half the cold risk. These findings do not establish an equivalent benefit from starting vitamin C after symptoms appear: seven therapeutic comparisons covering 3,249 episodes showed no consistent reduction in duration or severity. (cochrane.org)

Echinacea and probiotics illustrate the difficulty of treating heterogeneous products as single interventions. A 2014 Cochrane review of echinacea included 24 double-blind trials and 4,631 participants, but preparations differed in plant species, plant parts and extraction methods; clinically relevant treatment benefits were not convincingly demonstrated. A 2022 Cochrane review found that probiotics might reduce the proportion of participants experiencing at least one acute upper respiratory tract infection by about 24% and shorten episodes by approximately 1.22 days. Confidence in these estimates was low. The probiotic studies addressed a broader category of respiratory infections rather than exclusively laboratory-confirmed colds, and their results do not establish equivalent effects for every strain or commercial formulation. (cochrane.org)

An enzyme-based mouth spray provides a concrete example of experimental testing. A manufacturer-supported pilot study conducted in Sweden in 2013 and published by Mats Clarsund and colleagues in 2017 randomly assigned 46 healthy adults to ColdZyme, containing glycerol and cod trypsin, or placebo before nasal inoculation with rhinovirus 16. The proposed mechanism was a protective barrier on the oropharyngeal mucosa. Participants used the spray six times daily for 11 days. Exploratory analyses reported lower cumulative throat viral load among participants with detectable infection and 3.0 rather than 6.5 symptomatic days among those developing symptomatic colds. However, the investigators judged the prespecified peak-viral-load endpoint unreliable; the favorable exploratory findings did not establish prevention of infection. (file.scirp.org)

Randomized controlled trials distinguish treatment effects from spontaneous recovery and placebo-associated changes, while systematic reviews assess consistency, bias and uncertainty across trials. Prespecified outcomes are especially important when studies measure numerous symptoms and time points. A larger ColdZyme trial published in 2023 randomized 701 adults, of whom 438 developed cold symptoms and started treatment; its primary quality-of-life endpoint and major secondary endpoints showed no statistically significant between-group differences. On June 16, 2026, PLOS ONE issued an expression of concern because the report emphasized favorable exploratory findings without adequately reflecting the unsuccessful prespecified outcomes. (journals.plos.org)

Economic and public-health burden

The economic burden of colds arises from their high frequency, healthcare use, and disruption of work and caregiving. A 2003 United States study by A. Mark Fendrick, Arnold S. Monto, and colleagues surveyed 4,051 households in 2000–2001 and extrapolated approximately 500 million non-influenza-related viral respiratory infections annually. Estimated annual costs approached US$40 billion: US$17 billion in direct costs and US$22.5 billion in indirect costs. Direct costs included outpatient consultations, prescription and nonprescription medicines, and infectious complications; indirect costs reflected productivity losses from illness-related absence and parents’ absence to care for children. These are historical estimates for a broader category than laboratory-confirmed common colds, not current expenditures or a count of virologically verified infections. Their magnitude depended on extrapolating self-reported illness and treatment patterns to the national population. (pubmed.ncbi.nlm.nih.gov)

School and workplace disruption also occurs among people who never consult a clinician, so healthcare records capture only part of the burden. In a community study published in 2022, rhinovirus or enterovirus was detected in 885 acute respiratory illness episodes. Among the 199 episodes for which medical care was sought, 47.7% involved missed work or school, compared with 16.4% of the 686 episodes without medical attendance. Median illness duration was seven and five days, respectively. These findings document the burden outside clinics, but the comparison does not show that seeking care caused greater absence: medically attended illnesses were also longer-lasting. The assay grouped rhinoviruses and enteroviruses together, rather than attributing every episode specifically to rhinovirus. (onlinelibrary.wiley.com)

Cold-associated viruses also generate hospital and asthma care costs, although severe virus-associated disease should not be counted as uncomplicated colds. Population-based surveillance in Nashville, Tennessee, and Rochester, New York, during October 2000–September 2001 detected rhinovirus in 156 of 592 hospitalized children younger than five years who had respiratory symptoms or fever. The estimated rhinovirus-associated hospitalization rate was 4.8 per 1,000 children annually, rising to 17.6 per 1,000 infants younger than six months. Among children with a history of asthma or wheezing, the estimated rate was 25.3 per 1,000, compared with 3.1 per 1,000 among those without that history. These were associated hospitalization rates: viral detection did not establish rhinovirus as the sole cause of every admission. (pmc.ncbi.nlm.nih.gov)

Inappropriate antibiotic prescribing adds avoidable drug exposure and contributes to antibiotic resistance, making respiratory consultations an important target for stewardship. Antibiotics do not treat viral colds. (portugues.cdc.gov) In a 2016 randomized controlled trial, Daniella Meeker and colleagues studied 248 clinicians across 47 primary-care practices in Boston and Los Angeles. Electronic-record prompts requiring a written justification for antibiotic prescribing reduced inappropriate prescribing by an additional 7.0 percentage points relative to the control-group change; emails comparing clinicians with low-prescribing peers produced an additional 5.2-point reduction. The outcomes covered nonspecific upper respiratory infections, acute bronchitis, and influenza, rather than colds alone. Merely displaying suggested nonantibiotic alternatives did not produce a statistically significant improvement relative to controls. (pubmed.ncbi.nlm.nih.gov)

Exposure and access to care vary with social determinants of health. A King County, Washington, study of 23,498 symptomatic participants tested during June 2020–July 2022 found that households containing five or more people were associated with rhinovirus positivity; household size, however, was not a direct measurement of crowding per room. (pmc.ncbi.nlm.nih.gov) Housing conditions are also relevant to broader respiratory morbidity: a New Zealand case-control study linked damp and mouldy housing with early-childhood hospital admissions for acute respiratory infection, without establishing a cold-specific effect. (thorax.bmj.com) Employment conditions affect both attendance and healthcare access. Research on US workers with medically attended respiratory illness in 2017–2018 associated paid leave with fewer days spent at the workplace while ill. A separate nationally representative analysis of 2017–2019 data found that low-wage workers had less job flexibility and less access to paid sick leave, while paid leave was associated with greater use of office-based care. (pubmed.ncbi.nlm.nih.gov)

Surveillance and molecular epidemiology

Laboratory-based public-health surveillance tracks cold-associated viruses through respiratory specimens rather than through a register of common-cold diagnoses. In the United States, the National Respiratory and Enteric Virus Surveillance System (NREVSS) receives voluntary weekly reports of tests performed and positive results from participating laboratories. Its respiratory-virus data include rhinoviruses/enteroviruses, common human coronaviruses, adenoviruses, parainfluenza viruses and human metapneumovirus. Nucleic acid amplification tests, including reverse-transcription polymerase chain reaction (RT-PCR), provide the basis for these reports. Weekly percentage positivity is calculated as positive tests divided by all tests performed for the relevant target, multiplied by 100; it measures detection among tested specimens, not the percentage of the general population experiencing a cold. (cdc.gov)

The resolution of surveillance depends on the assay. Many multiplex respiratory panels report a combined “rhinovirus/enterovirus” result without identifying either the species or the individual type, so an increase in that category cannot automatically be attributed to rhinoviruses. In a 2022 analysis, Kevin C. Ma and colleagues combined NREVSS results with emergency-department records and pediatric sentinel testing. Across 473 reporting laboratories, rhinovirus/enterovirus positivity rose from 15.8% in epidemiological week 32 to 31.4% in week 35. Additional enterovirus D68-specific RT-PCR testing in the pediatric network helped identify a contribution from that virus. This illustrates the distinction between broad circulation monitoring and targeted investigation of the organisms responsible for a surveillance signal. (cdc.gov)

Nucleotide sequencing provides finer resolution by assigning rhinoviruses to species A, B or C and to genetically defined types. Traditional molecular surveillance has concentrated on the capsid-coding VP1 region or the VP4/VP2 region; comparisons with reference sequences and phylogenetic analysis distinguish types that a routine diagnostic panel groups together. (pmc.ncbi.nlm.nih.gov) Regional sampling shows that circulation is not usually dominated by a single type. Temitope O. C. Faleye and colleagues examined nasopharyngeal specimens from 248 people attending a southwestern United States university clinic with influenza-like illness between October 1, 2020, and March 31, 2021. They identified at least 13 rhinovirus genotypes spanning all three species, including an unassigned rhinovirus A genotype, and reported 16 variants within the sampled community. (pubmed.ncbi.nlm.nih.gov)

Whole-genome sequencing extends analysis beyond these short typing regions, allowing comparisons of capsid and nonstructural genes and investigation of recombination and variation within a genotype. A western Washington study generated 1,078 rhinovirus genomes from symptomatic and asymptomatic individuals sampled during February–July 2021 and November–December 2022. It detected 99 of the 168 known genotypes used in its reference classification; more than 20% of recognized genotypes within each species circulated during every month examined. Whole-genome phylogenetic analyses also revealed divergent lineages within individual genotypes, intergenotypic recombination and changes in genotype clusters between the two sampling periods. Thus, a stable species-level detection rate can conceal considerable turnover in the genetically distinct viruses circulating locally. (pmc.ncbi.nlm.nih.gov)

These systems do not directly count the incidence of common-cold episodes. Mild illnesses managed outside healthcare produce no clinical specimen, while laboratory datasets preferentially capture people who seek care and are selected for testing. Interpretation also depends on the surveillance population, reporting delays and changes in healthcare-seeking or testing practices—limitations explicitly identified in the 2022 CDC analysis. Consequently, changes in positive-test counts or positivity cannot be interpreted as proportional changes in population incidence without considering how specimens were obtained. Laboratory surveillance establishes which viral groups are being detected and when; estimates of the total number of colds require population-based sampling or assumptions about the illnesses absent from laboratory reports. (cdc.gov)

Historical understanding of colds

Ancient and medieval descriptions of catarrh encompassed nasal discharge, coughing and other respiratory complaints, rather than a disease defined by a particular infectious agent. The term derived from a Greek word for “flowing down.” In the medicine of Galen, the second-century CE physician, catarrh was explained as excessive, improperly balanced bodily fluid produced in the brain and descending through the palate or into the respiratory tract. This humoral explanation remained influential through medieval medicine and into the seventeenth century. Its anatomical assumptions differed fundamentally from modern accounts of nasal secretion and inflammation; historical references to catarrh therefore cannot automatically be identified as cases of the modern common cold. (cambridge.org)

The development of germ theory in the late nineteenth century redirected investigation toward microorganisms, initially encouraging a search for a bacterial cause of colds. No bacterium emerged as their consistent primary cause. A decisive alternative came from filtration experiments: in 1914, Walther Kruse reported that nasal secretions from people with colds could still transmit illness after passage through filters intended to remove bacteria. In 1930, Perrin H. Long, James A. Doull, Janet M. Bourn and Emily McComb reported experimental infections in nine of fifteen people inoculated with bacteria-free filtrates of nasopharyngeal washings. Transmission through successive passages strengthened the evidence for a replicating, filterable agent—what researchers then called a virus—although it did not identify the individual viruses involved. (cabinetmagazine.org)

Dedicated research facilities made controlled transmission studies possible on a larger scale. Britain’s Medical Research Council and Ministry of Health established the Common Cold Unit near Salisbury in 1946, initially under Christopher Andrewes; its first volunteer trials took place that July. David Tyrrell succeeded Andrewes as head in 1962. The unit had twelve flats accommodating up to thirty volunteers, who participated in ten-day experiments under isolation conditions. Nasal inoculation, placebo controls, double-blind procedures and systematic symptom recording allowed researchers to distinguish experimentally induced illness from unrelated infections and expectations about treatment. The unit also investigated island communities and respiratory illness in children, connecting laboratory experiments with epidemiological observations. (wellcomecollection.org)

During the 1950s, tissue-culture methods began turning the inferred filterable agents into viruses that could be propagated and compared. Winston H. Price of Johns Hopkins University published an early rhinovirus isolation in December 1956. British work also contributed: Andrewes and colleagues reported cultivation of the D.C. strain in human embryonic lung cultures in 1953, although its identification as a rhinovirus was established later. These overlapping findings make the discovery a sequence of isolation, cultivation and classification rather than a single event. By 1966, researchers at Salisbury could describe experiments with a particular rhinovirus instead of merely administering infectious nasal washings of uncertain composition. (pubmed.ncbi.nlm.nih.gov)

Human coronaviruses were identified through methods that overcame the limitations of ordinary cell cultures. In 1965, Tyrrell and Malcolm Bynoe reported cultivating the cold-associated agent B814 in organ cultures of human embryonic trachea and demonstrating its infectivity in volunteers. At the University of Chicago, Dorothy Hamre and John J. Procknow independently reported another respiratory virus in 1966, subsequently known as 229E. June Almeida and Tyrrell’s electron-microscopy work in 1967 showed the distinctive surface projections of these agents; the name coronavirus, referring to their crown-like appearance, was announced in Nature in 1968. Identification of multiple viral causes supplied the etiological basis for distinguishing uncomplicated colds from bacterial disease and for recognizing why antibiotics do not treat them. In research, defined viral strains enabled reproducible challenge experiments, comparisons of symptoms and antibody responses, and controlled investigations of prevention and treatment. (bmj.com)

Folk beliefs and the cold-exposure hypothesis

The belief that wet feet, wet hair, rain or a sudden chill causes a cold has antecedents in older medical explanations of nasal discharge. In humoral medicine, phlegm was classified as cold and moist. The historical concept of catarrh, derived from the Greek for a flowing down, described excess humoral fluid descending from the head. Cold was thought to disturb the brain and provoke this flow toward the throat and lungs. This explanation preceded the recognition of respiratory viruses; it treated cooling as a cause of illness rather than as a possible influence on exposure or host susceptibility. (iranicaonline.org)

Controlled infection experiments have not consistently supported the folk belief. In 1968, R. Gordon Douglas Jr., Keith M. Lindgren and Robert B. Couch studied experimentally induced rhinovirus type 15 infection in 44 volunteers without detectable antibody to that virus. Cold-exposure procedures included a room at $4^\circ\mathrm{C}$ and immersion in water at $32^\circ\mathrm{C}$, applied at selected stages from inoculation through recovery. The investigators assessed infection, illness severity, virus shedding and immune responses, but failed to demonstrate an effect of chilling on the experimentally induced cold. Such studies tested defined exposures under controlled conditions, rather than every circumstance in which naturally acquired infection might coincide with cold weather. (nejm.org)

A different result came from Claire Johnson and Ronald Eccles’s 2005 randomized controlled trial at Cardiff University. Among 180 healthy participants, 90 underwent foot chilling and 90 a control procedure. During the following four or five days, 13 chilled participants reported having a cold, compared with five controls—14.4% versus 5.6%, with $P=0.047$. There was no immediate increase in symptom scores after chilling. Crucially, the reported outcome was the development of symptoms, not laboratory-confirmed acquisition of a respiratory virus. The authors therefore called for further investigation of the relationship between symptom generation and infection. The findings do not establish that wet feet transmit infection or that chilling alone produces a viral cold. (pubmed.ncbi.nlm.nih.gov)

The cold-exposure hypothesis also encompasses several distinct mechanisms. Eccles proposed that cooling the body surface could cause reflex constriction of blood vessels in the upper airway, reducing local defenses and allowing an already present, symptomless infection to become symptomatic. This remains a hypothesis rather than an established explanation of the foot-chilling result. Direct cooling of airway cells has stronger experimental mechanistic support: in 2015, Ellen Foxman and colleagues found that mouse airway cells mounted stronger interferon and other antiviral responses at $37^\circ\mathrm{C}$ than at $33^\circ\mathrm{C}$, helping restrict rhinovirus replication at the warmer temperature. These cell experiments concern local innate immunity, not proof that ordinary outdoor exposure increases human cold incidence. (researchgate.net)

A study by Di Huang and colleagues, published online in December 2022 and in a February 2023 journal issue, examined another local defense mechanism. Nasal epithelial cells released extracellular vesicles that carried antiviral material and could bind viruses as decoys. Applying a cold-associated reduction in nasal temperature to laboratory cultures reduced vesicle release by 41.9%, alongside reductions in antiviral cargo and receptor-binding activity. This supplies a biologically plausible pathway through which nasal cooling could weaken defenses, but it was not a community trial measuring whether chilled people subsequently acquired more colds. (pmc.ncbi.nlm.nih.gov)

Seasonal associations involve factors beyond personal chilling. Cold weather can change indoor crowding and contact patterns; heating cold outdoor air lowers indoor relative humidity, while dry conditions can affect airway defenses and the behavior of respiratory particles. Temperature and humidity also influence virus stability, with effects that differ among viruses. Consequently, a seasonal rise in respiratory infections cannot by itself identify direct cooling of the body as the cause: outdoor temperature covaries with indoor conditions, behavior and opportunities for transmission. Evidence concerning influenza or one laboratory model likewise cannot automatically be extended to every virus that produces cold symptoms. (pubmed.ncbi.nlm.nih.gov)

Open questions and current research

A central question is how much recurrent cold illness reflects waning immunological memory, rather than exposure to antigenically different viruses. Rhinovirus immunity does not invariably disappear quickly: an experimental study of 17 volunteers found protection against the same virus type one year after infection in participants who retained specific antibodies. A 2023 study by Yury Bochkov and colleagues, combining infection records from 3,199 children with longitudinal antibody measurements, found persistent neutralizing responses to rhinoviruses A and C but limited cross-neutralization between types. These findings shift the research problem toward distinguishing durable type-specific protection from protection at the nasal surface, and identifying which immune measurements predict resistance to infection rather than merely reduced illness. (pmc.ncbi.nlm.nih.gov)

Interactions between respiratory viruses are being investigated through viral interference, in which one infection activates defenses that restrict another. In 2020, Anchi Wu, Ellen Foxman and colleagues showed that rhinovirus infection induced antiviral genes in cultured human airway epithelium and strongly inhibited influenza A infection introduced three days later; blocking interferon signaling removed this protection. Human observational evidence followed: a 2025 HEROS cohort study tested 10,493 nasal swabs from 1,156 participants and associated rhinovirus infection during the preceding 30 days with a 48% lower subsequent risk of SARS-CoV-2 infection. Children had higher expression of the associated antiviral gene signature. This supports investigation of short-lived innate immune protection, rather than antibody cross-reactivity, but the observational association does not establish that rhinovirus prevents COVID-19. The duration and population-level importance of interference remain unresolved. (pmc.ncbi.nlm.nih.gov)

The airway microbiome may help explain why comparable viral exposures produce different responses. In a 2018 experimental rhinovirus A39 study involving 152 adults, Markus Lehtinen and colleagues identified six nasal bacterial-community clusters. Preinfection community composition was associated with subsequent viral loads and inflammatory profiles: Moraxella-dominated communities generally showed larger increases in inflammatory mediators, whereas Staphylococcus-dominated communities showed smaller increases. However, the overall comparison of total symptom scores between clusters did not reach statistical significance. Neither rhinovirus infection nor the tested oral probiotic significantly changed community composition. Whether bacteria directly modify antiviral defenses, or instead mark other host and environmental differences, requires experiments beyond these exploratory associations. (pmc.ncbi.nlm.nih.gov)

Host genetic variation provides a more directly demonstrated mechanism of differential susceptibility. In 2015, Bochkov and colleagues identified CDHR3 as a receptor permitting rhinovirus C entry and replication. The rs6967330 variant, which substitutes tyrosine for cysteine at amino-acid position 529, had previously been associated with severe childhood asthma exacerbations. In transfected cells, the variant produced approximately tenfold increases in viral binding and progeny yield compared with the reference receptor. Research must distinguish such receptor-specific effects from broader susceptibility to colds: this finding concerns rhinovirus C and cannot explain responses to all cold-causing viruses. (pubmed.ncbi.nlm.nih.gov)

For vaccine development, an unresolved issue is whether protection can be broadened by combining many virus types or by targeting conserved components. Sujin Lee and colleagues demonstrated in 2016 that a 50-valent inactivated rhinovirus preparation induced neutralizing antibodies against numerous included types in rhesus macaques; this established immunogenicity, not clinical protection in humans. A separate mouse study using the conserved capsid precursor VP0 enhanced airway T-cell responses and accelerated viral clearance after challenge with different rhinovirus serotypes. Antiviral development faces complementary problems of breadth, treatment timing and resistance: pleconaril studies recovered viruses with reduced susceptibility from 10.7% of treated participants and fully resistant viruses from 2.7%. (pubmed.ncbi.nlm.nih.gov)

Human challenge studies allow candidate interventions to be tested against a defined virus with precisely timed exposure. A randomized, double-blind trial published on September 25, 2026 assigned 64 participants to intranasal 2-deoxy-D-glucose or placebo before rhinovirus 39 challenge. Rhinovirus-associated illness occurred in 59.3% and 58.6% of the respective evaluable groups, with no significant difference in viral concentrations or symptom scores; the trial stopped at a prespecified interim analysis. Such models can identify ineffective candidates early, but results from one challenge strain do not establish efficacy against the diverse viruses responsible for naturally acquired colds. (pubmed.ncbi.nlm.nih.gov)

References

1. Common Cold - Infectious Disease - Merck Manual Professional Editionmerckmanuals.com
2. The natural history of community-acquired common colds symptoms assessed over 4-years - PubMedpubmed.ncbi.nlm.nih.gov
3. Signs and Symptoms of Flucdc.gov
4. The Common Cold - PMCpmc.ncbi.nlm.nih.gov
5. Preventing and Treating Common Coldstacks.cdc.gov
6. Consumer attitudes on cough and cold: US (ACHOO) survey results - PubMedpubmed.ncbi.nlm.nih.gov
7. Viruses and Bacteria in the Etiology of the Common Coldpmc.ncbi.nlm.nih.gov
8. Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Rhinovirus Induced Common Coldctv.veeva.com
9. Seasonality of Common Human Coronaviruses, United States, 2014–2021wwwnc.cdc.gov
10. Common Human Coronavirusescdc.gov
11. About Common Coldcdc.gov
12. People with symptoms of a respiratory infection including COVID-19gov.uk
13. Multiple receptors involved in human rhinovirus attachment to live cellspmc.ncbi.nlm.nih.gov
14. Family: Picornaviridae | ICTVictv.global
15. ICTV Virus Taxonomy Profile: Coronaviridae 2023pmc.ncbi.nlm.nih.gov
16. Coronaviridae | ICTVictv.global
17. Human rhinovirus subviral a particle binds to lipid membranes over a twofold axis of icosahedral symmetrypubmed.ncbi.nlm.nih.gov
18. ICAM-1 Binding Rhinoviruses Enter HeLa Cells via Multiple Pathways and Travel to Distinct Intracellular Compartments for Uncoatingpmc.ncbi.nlm.nih.gov
19. Low pH-Triggered Beta-Propeller Switch of the Low-Density Lipoprotein Receptor Assists Rhinovirus Infectionpmc.ncbi.nlm.nih.gov
20. Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replicationpubmed.ncbi.nlm.nih.gov
21. Receptor Priming of Major Group Human Rhinoviruses for Uncoating and Entry at Mild Low-pH Environmentspmc.ncbi.nlm.nih.gov
22. Temperature-dependent innate defense against the common cold virus limits viral replication at warm temperature in mouse airway cellspubmed.ncbi.nlm.nih.gov
23. Two interferon-independent double-stranded RNA-induced host defense strategies suppress the common cold virus at warm temperaturepmc.ncbi.nlm.nih.gov
24. Transmission of experimental rhinovirus infection by contaminated surfaces.pubmed.ncbi.nlm.nih.gov
25. Aerosol transmission of rhinovirus coldspubmed.ncbi.nlm.nih.gov
26. Transmission of rhinovirus in the Utah BIG-LoVE families: Consequences of age and household structurepmc.ncbi.nlm.nih.gov
27. Changes to Endemic Respiratory Virus Circulation and Testing Before, During, and After the COVID-19 Pandemicpubmed.ncbi.nlm.nih.gov
28. Histopathologic examination and enumeration of polymorphonuclear leukocytes in the nasal mucosa during experimental rhinovirus coldspubmed.ncbi.nlm.nih.gov
29. Respiratory virus infection of monolayer cultures of human nasal epithelial cellspubmed.ncbi.nlm.nih.gov
30. Role of double-stranded RNA pattern recognition receptors in rhinovirus-induced airway epithelial cell responsespmc.ncbi.nlm.nih.gov
31. Co-ordinated Role of TLR3, RIG-I and MDA5 in the Innate Response to Rhinovirus in Bronchial Epitheliumpmc.ncbi.nlm.nih.gov
32. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infectionpubmed.ncbi.nlm.nih.gov
33. Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throatpubmed.ncbi.nlm.nih.gov
34. Nasal challenge studies with bradykinin: influence upon mediator generationpubmed.ncbi.nlm.nih.gov
35. Is histamine responsible for the symptoms of rhinovirus colds? A look at the inflammatory mediators following infectionpubmed.ncbi.nlm.nih.gov
36. Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus coldspubmed.ncbi.nlm.nih.gov
37. Prechallenge antibodies moderate disease expression in adults experimentally exposed to rhinovirus strain hankspubmed.ncbi.nlm.nih.gov
38. The time course of the humoral immune response to rhinovirus infectionpubmed.ncbi.nlm.nih.gov
39. Proposals for the classification of human rhinovirus species A, B and C into genotypically assigned typespubmed.ncbi.nlm.nih.gov
40. Rhinovirus-specific T cells recognize both shared and serotype-restricted viral epitopespubmed.ncbi.nlm.nih.gov
41. T-bet+ Memory B Cells Link to Local Cross-Reactive IgG upon Human Rhinovirus Infectionpmc.ncbi.nlm.nih.gov
42. Immunological memory diversity in the human upper airwaypmc.ncbi.nlm.nih.gov
43. The Common Cold Is Associated With Protection From SARS-CoV-2 Infectionspubmed.ncbi.nlm.nih.gov
44. The common cold is associated with protection from SARS-CoV-2 infectionsdigitalcommons.wustl.edu
45. Common Cold - Infections - Merck Manual Consumer Versionmerckmanuals.com
46. Cold Versus Flucdc.gov
47. Symptoms of Coronavirusstacks.cdc.gov
48. Manage Common Coldcdc.gov
49. Nasal Congestion and Rhinorrhea - Merck Manual Professional Editionmerckmanuals.com
50. Clinical Guidance for Group A Streptococcal Pharyngitiscdc.gov
51. Outpatient Clinical Care for Adultscdc.gov
52. Testing and Respiratory Virusescdc.gov
53. Improved Molecular Typing Assay for Rhinovirus Species A, B, and Cpmc.ncbi.nlm.nih.gov
54. Viral Upper Respiratory Tract Infection and Otitis Media Complication in Young Childrenpmc.ncbi.nlm.nih.gov
55. Viral-Bacterial Interactions and Risk of Acute Otitis Media Complicating Upper Respiratory Tract Infectionpmc.ncbi.nlm.nih.gov
56. About Rhinovirusescdc.gov
57. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 productionpmc.ncbi.nlm.nih.gov
58. Experimental Rhinovirus Infection as a Human Model of Chronic Obstructive Pulmonary Disease Exacerbationpmc.ncbi.nlm.nih.gov
59. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary diseasepubmed.ncbi.nlm.nih.gov
60. Human rhinovirus detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortalitypubmed.ncbi.nlm.nih.gov
61. Clinical Study of Human Coronavirus NL63, OC43, 229E, HKU1 Infentions in Hospitalized Children from 2015 to 2020pubmed.ncbi.nlm.nih.gov
62. Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populationspubmed.ncbi.nlm.nih.gov
63. Preventing and Managing Common Coldcdc.gov
64. Common Cold Fact Sheetdoh.dc.gov
65. Preventing and Managing the Common Coldcdc.gov
66. Colds in childrencaringforkids.cps.ca
67. Rhinovirus transmission within families with children: incidence of symptomatic and asymptomatic infectionspubmed.ncbi.nlm.nih.gov
68. Daycare attendance and respiratory tract infections: a prospective birth cohort studyutupub.fi
69. Daycare attendance and respiratory tract infections: a prospective birth cohort studypmc.ncbi.nlm.nih.gov
70. Non-steroidal anti-inflammatory drugs for the common coldcochrane.org
71. Should You Give Kids Medicine for Coughs and Colds?fda.gov
72. Decongestantsnhs.uk
73. New reviewari.cochrane.org
74. Outpatient Clinical Care for Pediatric Populationscdc.gov
75. Use Caution When Giving Cough and Cold Products to Kidsfda.gov
76. Hygiene and Respiratory Viruses Preventioncdc.gov
77. How to Protect Yourself & Othersstacks.cdc.gov
78. Do physical measures such as hand-washing or wearing masks stop or slow down the spread of respiratory viruses?cochrane.org
79. A randomized trial of the efficacy of hand disinfection for prevention of rhinovirus infectionpubmed.ncbi.nlm.nih.gov
80. Effect of cleaning and disinfection of toys on infectious diseases and micro-organisms in daycare nurseriespubmed.ncbi.nlm.nih.gov
81. Preventing Spread of Respiratory Viruses When You're Sickcdc.gov
82. Taking Steps for Cleaner Air for Respiratory Virus Preventioncdc.gov
83. Masks and Respiratory Viruses Preventioncdc.gov
84. Respiratory virus shedding in exhaled breath and efficacy of face masksnature.com
85. Clinical Significance of Rhinoviruses and Progress Toward Vaccinationpmc.ncbi.nlm.nih.gov
86. A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaquespubmed.ncbi.nlm.nih.gov
87. Zinc for the prevention and treatment of the common coldcochrane.org
88. Colds, Flu, and Complementary Health Approaches: Usefulness and Safetynccih.nih.gov
89. Vitamin C for preventing and treating the common coldcochrane.org
90. Echinacea for preventing and treating the common coldcochrane.org
91. Can probiotics (live micro-organisms) prevent upper respiratory tract infections such as the common cold?cochrane.org
92. A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Coldfile.scirp.org
93. Early intervention with ColdZyme mouth spray after self-diagnosis of common cold: A randomized, double-blind, placebo-controlled studyjournals.plos.org
94. The economic burden of non-influenza-related viral respiratory tract infection in the United States.pubmed.ncbi.nlm.nih.gov
95. Rhinovirus-Associated Hospitalizations in Young Childrenpmc.ncbi.nlm.nih.gov
96. Manage Common Coldportugues.cdc.gov
97. 2022 SPECIAL REPORT: COVID-19 U.S. Impact on Antimicrobial Resistancecdc.gov
98. Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices: A Randomized Clinical Trial.pubmed.ncbi.nlm.nih.gov
99. Trends in Risk Factors and Symptoms Associated With SARS-CoV-2 and Rhinovirus Test Positivity in King County, Washington, June 2020 to July 2022pmc.ncbi.nlm.nih.gov
100. Paid Leave and Access to Telework as Work Attendance Determinants during Acute Respiratory Illness, United States, 2017-2018pubmed.ncbi.nlm.nih.gov
101. High Job Flexibility And Paid Sick Leave Increase Health Care Access And Use Among US Workerspubmed.ncbi.nlm.nih.gov
102. Percent positivity of respiratory viruses by nucleic acid amplification tests (NAATs), as reported on the National Respiratory and Enteric Virus Surveillance System (NREVSS) Dashboarddata.cdc.gov
103. Increase in Acute Respiratory Illnesses Among Children and Adolescents Associated with Rhinoviruses and Enteroviruses, Including Enterovirus D68 — United States, July–September 2022cdc.gov
104. Surveillance of rhinovirus diversity among a university community identifies multiple types from all three species including an unassigned rhinovirus A genotype.pubmed.ncbi.nlm.nih.gov
105. Genomic Epidemiology and Evolution of Rhinovirus in Western Washington State, 2021–2022pmc.ncbi.nlm.nih.gov
106. Catarrh (VIII.23) - The Cambridge World History of Human Diseasecambridge.org
107. Virus Campcabinetmagazine.org
108. THE ETIOLOGY OF ACUTE UPPER RESPIRATORY INFECTION (COMMON COLD)pmc.ncbi.nlm.nih.gov
109. THE ISOLATION OF A NEW VIRUS ASSOCIATED WITH RESPIRATORY CLINICAL DISEASE IN HUMANSpubmed.ncbi.nlm.nih.gov
110. Identification of Rhinovirus Strain D.C.nature.com
111. Virology: Coronavirusesnature.com
112. Acute cooling of the feet and the onset of common cold symptomspubmed.ncbi.nlm.nih.gov
113. Cold exposure impairs extracellular vesicle swarm-mediated nasal antiviral immunitypmc.ncbi.nlm.nih.gov
114. Cold exposure impairs extracellular vesicle swarm-mediated nasal antiviral immunity — PubMedpubmed.ncbi.nlm.nih.gov
115. Seasonality of Respiratory Viral Infections — PubMedpubmed.ncbi.nlm.nih.gov
116. Seasonality of influenza and other respiratory virusespmc.ncbi.nlm.nih.gov
117. The time course of the humoral immune response to rhinovirus infectionpmc.ncbi.nlm.nih.gov
118. Rhinoviruses A and C elicit long-lasting antibody responses with limited cross-neutralizationpmc.ncbi.nlm.nih.gov
119. Interference between rhinovirus and influenza A virus: a clinical data analysis and experimental infection studypmc.ncbi.nlm.nih.gov
120. Nasal microbiota clusters associate with inflammatory response, viral load, and symptom severity in experimental rhinovirus challengepmc.ncbi.nlm.nih.gov
121. Cross-Serotype Immunity Induced by Immunization with a Conserved Rhinovirus Capsid Proteinpmc.ncbi.nlm.nih.gov
122. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinovirusespubmed.ncbi.nlm.nih.gov
123. 2-Deoxy-D-Glucose in a Human Rhinovirus Challenge Model: a Randomised, Double-blind Placebo-controlled phase 2a clinical trial.pubmed.ncbi.nlm.nih.gov